Targeted therapy for sarcomas

References

• JoensuuHRobertsPJSarlomo-RikalaMEffect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumorN Engl J Med2001344141052105611287975
   PubMed Web of Science ®Google Scholar
• van OosteromATJudsonIVerweijJEuropean Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupSafety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyLancet 272001358929114211423
   PubMed Web of Science ®Google Scholar
• DemetriGDvon MehrenMBlankeCDEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsN Engl J Med2002347747248012181401
   PubMed Web of Science ®Google Scholar
• BlankeCDDemetriGDvon MehrenMLong-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KITJ Clin Oncol200826462062518235121
   PubMed Web of Science ®Google Scholar
• BenjaminRSChoiHMacapinlacHAWe should desist using RECIST, at least in GISTJ Clin Oncol200725131760176417470866
   PubMed Web of Science ®Google Scholar
• HeinrichMCOwzarKCorlessCLCorrelation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupJ Clin Oncol200826335360536718955451
   PubMed Web of Science ®Google Scholar
• Debiec-RychterMSciotRLe CesneAEORTC Soft Tissue and Bone Sarcoma GroupItalian Sarcoma GroupAustralasian GastroIntestinal Trials GroupKIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEur J Cancer20064281093110316624552
   PubMed Web of Science ®Google Scholar
• BlayJYLe CesneARay-CoquardIProspective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma GroupJ Clin Oncol20072591107111317369574
   PubMed Web of Science ®Google Scholar
• Le CesneARay-CoquardIBuiBNFrench Sarcoma GroupDiscontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trialLancet Oncol2010111094294920864406
   PubMed Web of Science ®Google Scholar
• DemetriGDvan OosteromATGarrettCREfficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialLancet200636895441329133817046465
   PubMed Web of Science ®Google Scholar
• GeorgeSvon MehrenMHeinrichMCA multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU)J Clin Oncol20112915 May 20 Supplement10007
   Web of Science ®Google Scholar
• DemetriGDReichardtPKangY-KRandomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trialJ Clin Oncol201230 Abstract LBA10008
   Web of Science ®Google Scholar
• AdenisALe CesneANguyenBBMasitinib mesylate in imatinib-resistant advanced GIST: a randomized phase II trialJ Clin Oncol201230 Abstract 10007
   Web of Science ®Google Scholar
• Le CesneABlayJYBuiBNPhase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)Eur J Cancer20104681344135120211560
   PubMed Web of Science ®Google Scholar
• TrentJCWalthenKvon MehrenMA phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST)J Clin Oncol201129 Abstract 10006
   Google Scholar
• SchöffskiPReichardtPBlayJYA phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumorsAnn Oncol201021101990199820507881
   PubMed Web of Science ®Google Scholar
• DematteoRPBallmanKVAntonescuCRAmerican College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study TeamAdjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialLancet200928373(9669)1097110419303137
   PubMed Web of Science ®Google Scholar
• JoensuuHErikssonMHatrmannKTwelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO)Proc Am Soc Clin Oncol2011 Abstract LBA1
   Google Scholar
• EisenbergBLHarrisJBlankeCDPhase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665J Surg Oncol2009991424718942073
   PubMed Web of Science ®Google Scholar
• McAuliffeJCHuntKKLazarAJA randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosisAnn Surg Oncol200916491091918953611
   PubMed Web of Science ®Google Scholar
• RutkowskiPVan GlabbekeMRankinCJEuropean Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma GroupSouthwest Oncology GroupImatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trialsJ Clin Oncol201028101772177920194851
   PubMed Web of Science ®Google Scholar
• KérobDPorcherRVérolaOImatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patientsClin Cancer Res201016123288329520439456
   PubMed Web of Science ®Google Scholar
• CasaliPGMessinaAStacchiottiSImatinib mesylate in chordomaCancer200410192086209715372471
   PubMed Web of Science ®Google Scholar
• StacchiottiSLonghiAFerraresiVPhase II study of imatinib in advanced chordomaJ Clin Oncol201230991492022331945
   PubMed Web of Science ®Google Scholar
• MercierFGuiotMCBojanowskiMWTreatment of chordoma with imatinib complicated by intracranial hemorrhage: a case showing dissociation between biological effect and therapeutic outcomeJ Neurooncol2012107243543722120582
   PubMed Web of Science ®Google Scholar
• StacchiottiSTamboriniEMarrariAResponse to sunitinib malate in advanced alveolar soft part sarcomaClin Cancer Res20091531096110419188185
   PubMed Web of Science ®Google Scholar
• StacchiottiSNegriTZaffaroniNSunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effectAnn Oncol20112271682169021242589
   PubMed Web of Science ®Google Scholar
• GardnerKJudsonILeahyMActivity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcomaJ Clin Oncol20092715s Abstract 10523
   Google Scholar
• National Cancer InstitutePhase II study of cediranib (AZD2171) in patients with alveolar soft part sarcoma Available from: http://clinicaltrials.gov/show/NCT00942877. NLM identifier: NCT00942877Accessed July 25, 2013
   Google Scholar
• ParkMSPatelSRLudwigJAActivity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumorCancer2011117214939494721480200
   PubMed Web of Science ®Google Scholar
• StacchiottiSNegriTPalassiniESunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor responseMol Cancer Ther2010951286129720457621
   PubMed Web of Science ®Google Scholar
• Ray-CoquardIItalianoABompasEFrench Sarcoma Group (GSF/GETO)Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO)Oncologist201172260266
   Google Scholar
• MakiRGD’AdamoDRKeohanMLPhase II study of sorafenib in patients with metastatic or recurrent sarcomasJ Clin Oncol200927193133314019451436
   PubMed Web of Science ®Google Scholar
• AgulnikMYarberJLOkunoSHAn open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomasAnn Oncol201324125726322910841
   PubMed Web of Science ®Google Scholar
• SleijferSRay-CoquardIPapaiZPazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)J Clin Oncol200927193126313219451427
   PubMed Web of Science ®Google Scholar
• van der GraafWTBlayJYChawlaSPEORTC Soft Tissue and Bone Sarcoma GroupPALETTE study groupPazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialLancet201237998291879188622595799
   PubMed Web of Science ®Google Scholar
• BlayJYEl SayadiHThiessePGarretJRay-CoquardIComplete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)Ann Oncol200819482182218296418
   PubMed Web of Science ®Google Scholar
• GelderblomHPérolDChevreauCAn open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatmentJ Clin Oncol201331 Abstract 10516
   Web of Science ®Google Scholar
• ButrynskiJED’AdamoDRHornickJLCrizotinib in ALK-rearranged inflammatory myofibroblastic tumorN Engl J Med2010363181727173320979472
   PubMed Web of Science ®Google Scholar
• ScotlandiKPicciPTargeting insulin-like growth factor 1 receptor in sarcomasCurr Opin Oncol200820441942718525338
   PubMed Web of Science ®Google Scholar
• PrieurATirodeFCohenPDelattreOEWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3Mol Cell Biol200424167275728315282325
   PubMed Web of Science ®Google Scholar
• PappoASPatelSCrowleyJActivity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing’s sarcoma family of tumors (ESFT): Results of a phase II SARC studyJ Clin Oncol20102815s Abstract 10000
   Web of Science ®Google Scholar
• TapWDDemetriGBarnettePPhase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumorsJ Clin Oncol201230151849185622508822
   PubMed Web of Science ®Google Scholar
• OlmosDPostel-VinaySMolifeLRSafety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort studyLancet Oncol201011212913520036194
   PubMed Web of Science ®Google Scholar
• JuergensHDawNCGeoergerBPreliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcomaJ Clin Oncol201129344534454022025154
   PubMed Web of Science ®Google Scholar
• SubbiahVNaingABrownRETargeted morphoproteomic profiling of Ewing’s sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signaturesPLoS One 6201164e18424
   PubMed Web of Science ®Google Scholar
• ThomasDHenshawRSkubitzKDenosumab in patients with giant-cell tumour of bone: an open-label, phase 2 studyLancet Oncol201011327528020149736
   PubMed Web of Science ®Google Scholar
• BranstetterDGNelsonSDManivelJCDenosumab induces tumor reduction and bone formation in patients with giant-cell tumor of boneClin Cancer Res201218164415442422711702
   PubMed Web of Science ®Google Scholar
• DicksonMATapWDKeohanMLPhase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated LiposarcomaJ Clin Oncol201331162024202823569312
   PubMed Web of Science ®Google Scholar
• ItalianoALe CesneACassierPAGDC-0449 in patients with advanced chondrosarcomas: A French Sarcoma Group (FSG)/French and US. National Cancer Institutes phase II collaborative studyJ Clin Oncol201330 Abstract 10005
   Web of Science ®Google Scholar
• GounderMMDicksonMAWuNA first-in-human, phase Ib combination study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a hedgehog inhibitor, GDC-0449, with a Notch inhibitor, RO4929097, in patients with advanced sarcomaJ Clin Oncol201330 Abstract 10004
   Google Scholar
• VézinaCKudelskiASehgalSNRapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principleJ Antibiot (Tokyo)197528107217261102508
   PubMed Web of Science ®Google Scholar
• BakerHSidorowiczASehgalSNVézinaCRapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluationJ Antibiot (Tokyo)197831653954528309
   PubMed Web of Science ®Google Scholar
• EngCPSehgalSNVézinaCActivity of rapamycin (AY-22,989) against transplanted tumorsJ Antibiot (Tokyo)19843710123112376501094
   PubMed Web of Science ®Google Scholar
• WiederrechtGJSabersCJBrunnGJMartinMMDumontFJAbrahamRTMechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cellsProg Cell Cycle Res1995153719552353
   PubMedGoogle Scholar
• SteckPAPershouseMAJasserSAIdentification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNat Genet19971543563629090379
   PubMed Web of Science ®Google Scholar
• NeshatMSMellinghoffIKTranCEnhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTORProc Natl Acad Sci U S A20019818103141031911504908
   PubMed Web of Science ®Google Scholar
• FrumanDAWoodMAGjertsonCKKatzHRBurakoffSJBiererBEFK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cellsEur J Immunol19952525635717533090
   PubMed Web of Science ®Google Scholar
• SekulićAHudsonCCHommeJLA direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cellsCancer Res200060133504351310910062
   PubMed Web of Science ®Google Scholar
• JefferiesHBFumagalliSDennisPBReinhardCPearsonRBThomasGRapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6kEMBO J19971612369337049218810
   PubMed Web of Science ®Google Scholar
• GingrasACRaughtBSonenbergNeIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translationAnnu Rev Biochem19996891396310872469
   PubMed Web of Science ®Google Scholar
• SabatiniDMmTOR and cancer: insights into a complex relationshipNat Rev Cancer20066972973416915295
   PubMed Web of Science ®Google Scholar
• LoewithRJacintoEWullschlegerSTwo TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth controlMol Cell200210345746812408816
   PubMed Web of Science ®Google Scholar
• ZengZSarbassov dosDSamudioIJRapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AMLBlood200710983509351217179228
   PubMed Web of Science ®Google Scholar
• KimDHSarbassovDDAliSMmTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machineryCell2002110216317512150925
   PubMed Web of Science ®Google Scholar
• HaraKMarukiYLongXRaptor, a binding partner of target of rapamycin (TOR), mediates TOR actionCell2002110217718912150926
   PubMed Web of Science ®Google Scholar
• YonezawaKTokunagaCOshiroNYoshinoKRaptor, a binding partner of target of rapamycinBiochem Biophys Res Commun2004313243744114684181
   PubMed Web of Science ®Google Scholar
• HarrisTELawrenceJCJrTOR signalingSci STKE20032003212re1514668532
   PubMedGoogle Scholar
• NojimaHTokunagaCEguchiSThe mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motifJ Biol Chem200327818154611546412604610
   PubMed Web of Science ®Google Scholar
• WullschlegerSLoewithRHallMNTOR signaling in growth and metabolismCell2006124347148416469695
   PubMed Web of Science ®Google Scholar
• JiangBHLiuLZRole of mTOR in anticancer drug resistance: perspectives for improved drug treatmentDrug Resist Updat2008113637618440854
   PubMed Web of Science ®Google Scholar
• KimDHSarbassovDDAliSMGbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTORMol Cell200311489590412718876
   PubMed Web of Science ®Google Scholar
• FriasMAThoreenCCJaffeJDmSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2sCurr Biol200616181865187016919458
   PubMed Web of Science ®Google Scholar
• SarbassovDDAliSMKimDHRictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeletonCurr Biol200414141296130215268862
   PubMed Web of Science ®Google Scholar
• WullschlegerSLoewithROppligerWHallMNMolecular organization of target of rapamycin complex 2J Biol Chem200528035306973070416002396
   PubMed Web of Science ®Google Scholar
• PearceLRHuangXBoudeauJIdentification of Protor as a novel Rictor-binding component of mTOR complex-2Biochem J2007405351352217461779
   PubMed Web of Science ®Google Scholar
• JacintoELoewithRSchmidtAMammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitiveNat Cell Biol20046111122111815467718
   PubMed Web of Science ®Google Scholar
• FaivreSKroemerGRaymondECurrent development of mTOR inhibitors as anticancer agentsNat Rev Drug Discov20065867168816883305
   PubMed Web of Science ®Google Scholar
• KurmashevaRTHuangSHoughtonPJPredicted mechanisms of resistance to mTOR inhibitorsBr J Cancer200695895596016953237
   PubMed Web of Science ®Google Scholar
• RicciRMaggianoNCastriFRole of PTEN in gastrointestinal stromal tumor progressionArch Pathol Lab Med2004128442142515043466
   PubMed Web of Science ®Google Scholar
• SaitoTOdaYKawaguchiKPTEN/MMAC1 gene mutation is a rare event in soft tissue sarcomas without specific balanced translocationsInt J Cancer2003104217517812569572
   PubMed Web of Science ®Google Scholar
• WanXHelmanLJLevels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cellsOncogene200322508205821114603261
   PubMed Web of Science ®Google Scholar
• GibbonsJJDiscafaniCPetersonRThe effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse in vivoProc Am Assoc Cancer Res199940301 Abstract 2000
   Google Scholar
• HidalgoMBucknerJCErlichmanCA phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancerClin Cancer Res200612195755576317020981
   PubMed Web of Science ®Google Scholar
• RaymondEAlexandreJFaivreSSafety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancerJ Clin Oncol200422122336234715136596
   PubMed Web of Science ®Google Scholar
• AtkinsMBHidalgoMStadlerWMRandomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinomaJ Clin Oncol200422590991814990647
   PubMed Web of Science ®Google Scholar
• HudesGCarducciMTomczackPA phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)J Clin Oncol20062418S June 20 SupplementLBA4
   Google Scholar
• ChanSScheulenMEJohnstonSPhase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancerJ Clin Oncol200523235314532215955899
   PubMed Web of Science ®Google Scholar
• CarpenterJTRochéHCamponeMRandomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancerJ Clin Oncol20052316S June 1 Supplement564
   Google Scholar
• GalanisEBucknerJCMaurerMJNorth Central Cancer Treatment GroupPhase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group StudyJ Clin Oncol200523235294530415998902
   PubMed Web of Science ®Google Scholar
• FourouzeshBBucknerJAdjeiAPhase I, bioavailability and pharmacokinetic study of oral dosage of CCI-779 administered to patients with advanced solid malignancies. Proceedings of the 13th EORTC-NCI-AACr symposiumEur J Cancer200238Suppl 7S54 Abstract 16811858966
   PubMed Web of Science ®Google Scholar
• O’ReillyTVaxelaireJMullerMIn vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor modelsProc Am Assoc Cancer Res200243 Abstract 359
   Google Scholar
• LaneHASchnellCTheuerAAntiangiogenic activity of RAD001, an orally active anticancer agentProc Amer Assoc Cancer Res200243184
   Google Scholar
• O’DonnellAFaivreSJudsonIA phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumorsProc Am Soc Clin Oncol200322200 Abstract 803
   Google Scholar
• AmatoRJMisellatiAKhanMChiangSA phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)J Clin Oncol20062418S June 20 Supplement4530
   Google Scholar
• LerutERoskamsTGoossensEMolecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma (PC)J Clin Oncol20052316S June 1 Supplement3071
   Google Scholar
• ReardonDQuinnJARichJNA phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant gliomaJ Clin Oncol20062418S June 20 Supplement1580
   Google Scholar
• YaoJCPhanAChangDZPhase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET)J Clin Oncol20072518S June 20 Supplement450317906216
   PubMed Web of Science ®Google Scholar
• MiltonDTKrisMGAzzoliCGPhase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)J Clin Oncol20052316S June 1 Supplement7104
   Web of Science ®Google Scholar
• ClacksonTMetcalfCARiveraVMBroad anti-tumor activity of ap23573, an mTOR inhibitor in clinical developmentProc Am Soc Clin Oncol200322220 Abstract 882
   Google Scholar
• MitaMRowinskyEKGoldstonMLPhase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of AP23573, an mTOR inhibitor administered IV daily X5 every other week in patients with refractory or advanced malignanciesJ Clin Oncol20042214S Abstract 3076
   Google Scholar
• DesaiAAJanishLBerkLRA phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refractory or advanced malignancies: A pharmacokinetic (PK) and pharmacodynamic (PD) analysisJ Clin Oncol20042214S July 15 Supplement3150
   Google Scholar
• PerottiAMaurMViganòLPhase Ib pharmacokinetic (PK) and pharmacodynamic (PD) study to define the optimal dose for combining the mTOR inhibitor AP23573 with capecitabine (CAPE)J Clin Oncol20062418S June 20 Supplement3065
   Google Scholar
• FeldmanEGilesFRobozGA phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignanciesJ Clin Oncol20052316S June 1 Supplement663116170170
   PubMed Web of Science ®Google Scholar
• ChawlaSPTolcherAWStaddonAPUpdated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomasJ Clin Oncol20062418S June 20 Supplement9505
   Google Scholar
• BlayJYvan GlabbekeMVerweijJAdvanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapyEur J Cancer2003391646912504660
   PubMed Web of Science ®Google Scholar
• Le CesneABlayJYJudsonIPhase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trialJ Clin Oncol200523357658415659504
   PubMed Web of Science ®Google Scholar
• Le CesneAJudsonICrowtherDRandomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma GroupJ Clin Oncol200018142676268410894866
   PubMed Web of Science ®Google Scholar
• Van GlabbekeMVerweijJJudsonINielsenOSEORTC Soft Tissue and Bone Sarcoma GroupProgression-free rate as the principal end-point for phase II trials in soft-tissue sarcomasEur J Cancer200238454354911872347
   PubMed Web of Science ®Google Scholar
• SankhalaKKChawlaSPIagaruAEarly response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma using [18F]2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scanJ Clin Oncol20052316S June 1 Supplement9028
   Google Scholar
• ChawlaSPBlayJRay-CoquardILResults of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT)J Clin Oncol201129 Abstract 10005
   PubMed Web of Science ®Google Scholar
• OkunoSHMahoneyMRBaileyHHA multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS)J Clin Oncol20062418S June 20 Supplement9504
   Google Scholar
• SchuetzeSMBakerLHMakiRGSirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcomaJ Clin Oncol20062418S June 20 Supplement9503
   Google Scholar
• HeinrichMCCorlessCLBlankeCDMolecular correlates of imatinib resistance in gastrointestinal stromal tumorsJ Clin Oncol200624294764477416954519
   PubMed Web of Science ®Google Scholar
• van OosteromAReichardtPBlayJ-YA phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: study updateJ Clin Oncol20052316S June 1 Supplement9033
   Google Scholar
• SchwartzGKTapWDQinLXCixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialLancet Oncol201314437138223477833
   PubMed Web of Science ®Google Scholar
• QuekRWangQMorganJACombination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumorsClin Cancer Res201117487187921177764
   PubMed Web of Science ®Google Scholar
• LeobDMDeLorenzoKAChenARSA dose-finding study of temsirolimus and liposomal doxorubicin for patients with advanced soft tissue or bone sarcomaJ Clin Oncol201129 Abstract 10026
   Web of Science ®Google Scholar
• MovvaSBocklageTSchmitBPhase I study of irinotecan and temsirolimus in patients with refractory sarcomasJ Clin Oncol201129 Abstract 10027
   Google Scholar
• WagnerAJMalinowska-KolodziejIMorganJAClinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumorsJ Clin Oncol201028583584020048174
   PubMed Web of Science ®Google Scholar
• ItalianoADelcambreCHosteinITreatment with the mTOR inhibitor temsirolimus in patients with malignant PEComaAnn Oncol20102151135113720215136
   PubMed Web of Science ®Google Scholar